Ushida, Takahiro
Katayama, Yoichi
Hiasa, Yoichi
Nishihara, Makoto
Tajima, Fumihiro
Katoh, Shinsuke
Tanaka, Hirotaka
Maeda, Takeshi
Furusawa, Kazunari
Kakehi, Yoshihiro
Kikumori, Kunika
Kuroha, Masanori
Clinical trials referenced in this document:
Documents that mention this clinical trial
Long-Term Safety and Efficacy of Mirogabalin for Central Neuropathic Pain: A Multinational, Phase 3, 52-Week, Open-Label Study in Asia
https://doi.org/10.1007/s40122-023-00513-1
Usefulness of Mirogabalin in Central Neuropathic Pain After Stroke: Post Hoc Analysis of a Phase 3 Study by Stroke Type and Location
https://doi.org/10.1007/s40122-024-00616-3
Funding for this research was provided by:
Daiichi-Sankyo
Article History
Received: 21 December 2022
Accepted: 3 April 2023
First Online: 28 April 2023